• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UK Agency to Up the Ante on Trial Transparency

UK Agency to Up the Ante on Trial Transparency

August 3, 2020

Clinical trials in the UK will have to pay more attention to data transparency under a new strategy being developed by the National Health Service’s Health Research Authority (HRA) that would offer sponsors and researchers both support and sanctions.

HRA says in a policy paper issued last week that it will develop a strategy to ensure all trials are registered, results are reported and information is shared with trial participants. Currently, HRA says, 30 percent of UK trials are not registered, 25 percent of trials do not report results and only 10 percent share findings with trial participants.

The agency’s plan, which it intends to carry out over the next two years, includes taking the registration responsibility out of sponsors’ hands and registering trials itself. Reporting rates will be enhanced by establishing a standard format for final trial reports and sending reporting reminders to sponsors and investigators. HRA will improve participant communication by requiring researchers and sponsors to submit a lay summary of trial results for publication on the agency’s website.

The strategy also has a performance review component that includes publishing information on individual trials’ transparency performance and making an assessment of a sponsor’s compliance part of the approval process for new studies. HRA also plans to establish sanctions for noncompliance, although its policy paper does not specify how they will be determined.

To read the HRA plan, click here: https://bit.ly/39HzDbw.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing